Key Takeaways
- Johnson & Johnson stock reached a record peak of $264.98 before climbing to $268.69, posting a 3.70% single-day gain
- Over the past twelve months, JNJ shares have surged 71% in total returns
- Guggenheim set a new $270 price target with a Buy rating, projecting Q2 revenue at $25.48 billion
- The healthcare giant boosted its quarterly payout to $1.34 from $1.30, extending its dividend growth streak to 55 years
- Major institutional players including Vanguard, State Street, and Norges Bank have increased their holdings significantly
Johnson & Johnson shares reached unprecedented territory on Tuesday, initially peaking at $264.98 before advancing to $268.69 — marking a robust 3.70% climb for the session. This performance brings the pharmaceutical and medical devices giant’s market capitalization to approximately $646.8 billion.
The remarkable ascent represents a 71% surge across the trailing twelve-month period, with the stock’s yearly low of $154.21 now a distant memory.
At present trading levels, JNJ commands a price-to-earnings multiple of 31.02 and a PEG ratio of 2.58. The equity’s fifty-day moving average rests at $233.72, while the two-hundred-day moving average stands at $231.37 — both substantially beneath current price action.
Tuesday’s session saw volume reach 1.79 million shares, significantly lighter than the typical 8.41 million average. Such low-volume advances often signal methodical accumulation by institutional players rather than speculative momentum.
Wall Street Price Objectives Under Pressure
Guggenheim analysts recently elevated their price objective to $270 while reaffirming a Buy recommendation. The firm anticipates second-quarter revenue of $25.48 billion alongside earnings per share of $2.87.
Leerink Partners upgraded JNJ from Market Perform to Outperform this past May, establishing a $265 price objective — a threshold the stock has now exceeded. Wells Fargo maintains an Overweight stance with a $263 target.
The aggregate view from 27 Wall Street analysts yields a “Moderate Buy” consensus with an average price target of $257.13. The stock’s current trading level above this consensus suggests bullish momentum is outpacing Street expectations.
Bank of America and Barclays maintain neutral positions with Equal Weight ratings, targeting $254 and $255 respectively.
Financial Performance and Shareholder Distributions
The company’s latest quarterly results, disclosed on April 14, revealed earnings per share of $2.70, surpassing the Street consensus of $2.68. Revenue totaled $24.06 billion versus expectations of $23.60 billion — representing a 9.9% year-over-year expansion.
Management also announced an increase in the quarterly dividend to $1.34 from $1.30, distributed on June 9. This establishes an annualized dividend of $5.36, translating to approximately a 2.0% current yield.
J&J has now delivered 55 consecutive annual dividend increases, solidifying its status as a Dividend King. The current payout ratio stands at 61.97%.
Full-year 2026 earnings per share guidance ranges from $11.45 to $11.65, with Wall Street consensus forecasting $11.57.
Institutional Accumulation and Corporate Developments
Institutional ownership accounts for 69.55% of outstanding shares. Vanguard expanded its position by 3.73 million shares in Q4, elevating its total stake to 240.35 million. State Street increased holdings by 1.66 million to 133.87 million shares. Norges Bank initiated a fresh position valued at approximately $6.92 billion.
Moran Wealth Management grew its allocation by 15.4% during Q1, acquiring an additional 12,160 shares to reach 90,903 units worth $22.2 million.
Regarding insider transactions, Executive Vice President Kathryn Wengel divested 10,000 shares at $241.15 on June 11, trimming her holdings by 8.05%. She retains ownership of 114,288 shares valued at roughly $27.6 million.
On the operational front, J&J disclosed plans for a $1 billion-plus capital investment in its Jacksonville, Florida facilities to expand manufacturing capabilities for its Vision segment, including enhanced production capacity for ACUVUE contact lenses.
Additionally, fresh clinical data on IMAAVY (nipocalimab-aahu) for myasthenia gravis treatment was showcased through 12 scientific abstracts at the European Academy of Neurology 2026 Congress.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
